Free Republic

Recent research suggests a potential link between the diabetes drug pioglitazone and a reduced risk of dementia in people with newly diagnosed type 2 diabetes. The study, led by Dr. Eosu Kim from Yonsei University, analyzed data from 91,218 participants over an average of 10 years, showing that those taking pioglitazone were 16% less likely to develop dementia. This percentage rose to 37% in those taking the drug for four years. The effect was more pronounced in people with a history of ischemic heart disease or stroke. A study in the Neurology journal suggests that the diabetes drug pioglitazone may...

A medication originally used for patients with diabetes is the first to help people with heart failure and could revolutionize treatment. Early research had shown that Sodium-glucose co-transporter-2 (SGLT2) inhibitors could help around half of heart failure patients—those with a condition known as reduction ejection fraction. But new findings published today show that the medication could be beneficial for all heart failure patients—including those with a second type of heart failure called preserved ejection fraction. It is the first drug to provide a real benefit in terms of improving outcomes for these patients. And the research team say it will...

The diabetes drug exenatide is currently being investigated as a Parkinson's treatment in Phase 3 human trials Esbenklinker/Depositphotos ======================================================================== A large population-based cohort study, led by researchers from University College London, is suggesting some drugs used to treat diabetes may also prevent the onset of Parkinson’s disease. Along with prior research, these new findings help validate an upcoming Phase 3 human clinical trial set to test one particular diabetes drug in Parkinson’s patients. Following several years of conflicting studies, a large and somewhat definitive 2018 study confirmed a link between type 2 diabetes and Parkinson’s disease. Following several million subjects,...

NEW YORK (CBSNewYork/CNN) — A widely-used diabetes drug is being recalled after manufacturers found it contained unacceptably high levels of a cancer-causing contaminant. Indian pharmaceutical company Marksans Pharma Limited is recalling metformin hydrochloride extended-release tablets because their levels of NDMA, a “probable human carcinogen,” were higher than the acceptable daily intake limit of 96 nanograms per day, according to a recall published this week by the US Food and Drug Administration (FDA).Metformin tablets are used to treat type 2 diabetes and are designed to lower glucose levels.The recall applies to metformin tablets between 500 mg and 750 mg, sold under...

Although their goal was to cure diabetes, scientists may have stumbled onto a new medication to help treat the devastating effects of Alzheimer’s disease. According to a press release from researchers at Lancaster University, a new drug being tested for diabetes patients was found to have “significantly reversed memory loss” in test subjects and is now being examined as possible treatment for neurodegenerative disorders. The medication, known as a triple receptor drug — or “triple agonist” — reportedly works in multiple ways to protect the brain against degeneration and promote growth. Researchers say that a study of mice being given...

This morning, Roche announced that it was stopping all clinical trials of an experimental diabetes drug called aleglitazar because it was not preventing heart attacks and strokes as the company expected, but was causing side effects that reportedly included heart failure, kidney problems, and an increase in fractures....